Agree with your thoughts Cancun ... much of the 20 years of heavy lifting is done, and RVX has continually honed in on what exactly apabetalone does, and to/with whom. Much of the TLD problem is either/both under-powering or malady endpoint targeting. Still massive promise for "someday" for "somebody" ... 

Next step, identify what exactly is the next course of action to get it to market potentially FDA/EMA/Asia? ... break-through? Bolt-on? P3(s)?

I think "we" all mostly agree, seemingly, that a new and big (BP?) partnership or new owners altogether are needed. 

Then, the bigger picture becomes more clear for truer valuation that can be assessed and negotiated. BP and RVX will just have to decide where the happy median exists in partnership or buy out, relative to known information ... probably by early 2020 imho.

Warrants exercise buys time for several of the above to happen and become clearer, along with some diligence ... "if" the warrants funding raise happens? ... if the warrants don't happen, then not sure what happens next with operating funds, worst case potentially a fire sale? Can't believe the bigger investors would allow a fire sale with so much on the line for losses as well as potential gains further down the road, unless they believe it is good money after bad, which is hard for me to see.

Still pretty optimistic for a positive result and ROI, but I could use a mojito on a sunny beach also ... hard to really have a strong opinion due to a lack of "real" information, all speculation.

tick tock for regulatory and warrants info ... 

jmho's